| Budget Amount *help |
¥124,800,000 (Direct Cost: ¥96,000,000、Indirect Cost: ¥28,800,000)
Fiscal Year 2023: ¥23,400,000 (Direct Cost: ¥18,000,000、Indirect Cost: ¥5,400,000)
Fiscal Year 2022: ¥23,400,000 (Direct Cost: ¥18,000,000、Indirect Cost: ¥5,400,000)
Fiscal Year 2021: ¥23,400,000 (Direct Cost: ¥18,000,000、Indirect Cost: ¥5,400,000)
Fiscal Year 2020: ¥23,400,000 (Direct Cost: ¥18,000,000、Indirect Cost: ¥5,400,000)
Fiscal Year 2019: ¥31,200,000 (Direct Cost: ¥24,000,000、Indirect Cost: ¥7,200,000)
|
|---|
| Outline of Final Research Achievements |
This study aims to generate mouse artificial blastocysts and to derive stem cells from all cell lineages constituting a human blastocyst. In mice, we succeeded in establishing primitive endoderm stem cells (PrES cells) for the first time (Science 2022). In humans, we established a differentiation system from ES/iPS cells to TS cells and found that the primate-specific microRNA cluster C19MC is important in this process (Nat Commun 2022). Furthermore, we have established a new stem cell line from human yolk sac tissue.
|
